Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

More on the new study.

Published On: 2 June 2023

  • Ten-year-old XNK Therapeutics experiences rapid growing with own GMP facility

    XNK Therapeutics has expanded significantly in the past year and now has access to its own GMP-standard production lab.

  • Restart for Tullinge work hub

    Just before the pandemic, a research project was initiated in Tullinge in which residents were offered a place at a local work hub as an alternative to commuting to work. The hub is now seeing something of a reopening in a project aimed at increasing shared use and resource efficiency.

  • Vesna ready for the next step in the service of residents

    Vesna Jovic is now leaving her role as municipality director for Huddinge – after 28 years at the authority. Her next position is CEO for the Swedish Association of Local Authorities and Regions, SKL. As she leaves Huddinge, she can look back on the burgeoning development of Flemingsberg and Huddinge.

  • Curiosity took him from the lab to the stock market

    Mathias Svahn is a CEO who still collects the mail and makes the coffee, even as he ranks among the highflyers leading the development of drugs of the future. Curiosity has taken him from the lab to the helm of a listed company. And it all started with a pregnancy.

  • He has built up Sweden’s leading gene and cell therapy lab

    I drygt 20 år har Pontus Blomberg styrt stegen mot Vecura i Flemingsberg. Här har han tillsammans med sina medarbetare byggt upp Sveriges främsta labb inom gen- och cellterapi. Ett område som kan leda till botande behandlingar för såväl olika cancersjukdomar som Alzheimers.